VRTX Vertex Pharmaceuticals Incorporated

Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Kimberly A. White has been appointed Senior Vice President and Chief Communications Officer. Ms. White will begin her role with Vertex on May 21, 2018, and will report to Michael J. Parini, Executive Vice President, Chief Legal and Administrative Officer. In her role, Ms. White will be responsible for leading the global corporate communications function, spanning product communications, media relations, digital and social communications, internal communications, corporate social responsibility and community affairs. Ms. White most recently served as Global Chair of the Health Sector at Edelman.

“We are thrilled to welcome Kym to the leadership team and to have her extensive experience across industry here at Vertex,” said Michael Parini. “Kym has the skill, management capabilities and industry acumen we need to evolve our communications efforts as Vertex continues to emerge as a leading global biotechnology company.”

“Vertex is on an incredible growth trajectory and is transforming the lives of patients with serious diseases,” said Ms. White. “The opportunity to tell that story and help advance understanding of the work of the dedicated scientists and researchers at Vertex compelled me to join them in this mission.”

KIMBERLY WHITE BIOGRAPHY:

Ms. White is a seasoned communications professional who has provided strategic leadership to companies in the global healthcare and pharmaceutical industries both in-house and as an agency advisor. Her expertise includes corporate reputation, issues and crisis management, brand marketing, media relations, corporate identity, internal communications and executive positioning.

She spent the last seven years at Edelman, where she headed the agency’s global healthcare sector and led a team of 600 people worldwide. During her time at Edelman, Ms. White developed and implemented U.S. and global communications programs for a wide variety of companies and organizations in the healthcare industry. Before Edelman, she was the Chief Communications Officer at Baxter International Inc., where she led Baxter’s global communications function. Ms. White also spent more than 15 years with Ogilvy PR Worldwide, including as the Co-Managing Director of the agency’s global healthcare practice.

Last year, Ms. White was recognized as one of the top 10 health influencers by PR Week. She also served as a 2017 Cannes Health Lions Pharma Juror.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

Founded in 1989 in Cambridge, Mass., Vertex's headquarters is now located in Boston's Innovation District. Today, the company has research and development sites and commercial offices in the United States, Europe, Canada and Australia. Vertex is consistently recognized as one of the industry's top places to work, including being named to Science magazine's Top Employers in the life sciences ranking for eight years in a row.

For additional information and the latest updates from the company, please visit www.vrtx.com.

(VRTX-GEN)

EN
29/03/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vertex Pharmaceuticals Incorporated

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: September 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch